Search 

Based Singapore, to partner drug development for US/EU/ASEAN market. Founder background - Pharmacist background with PHD, School of Pharmacy London, UK - Worked in Early drug discover and development @ Novartis-UK , commercial side Manufacturing science and technology MS&T in Novartis - Singapore and - Global technical operations -GTO, MSD - Singapore; Drug Device combination products. - Involved in successful filing of several INDs applied the concepts to drug development in a virtual small Biotech, to prepare for Phase 3 clinical trials Partnering objectives - Partner with likeminded companies to address the challenges posed by Covid-19 pandemic - Entrepreneurship, Start-ups, Joint ventures, Fundraising Primary area of expertise Drug Development, IND, NDA, Process validation, CMC, Technology transfer, Digital medicines, Digital Therapies, Entrepreneurship

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.

CRUise is the largest SMO Network in MEA region, we are aiming to have a network of clinical research units and Key Opinion Leaders interested in Clinical Research. CRUise will ensure the quality of research by having a network with unified international standards.